Neuro-oncology Research
Ongoing Research
Researchers at the Center for Childhood Cancer Research are evaluating ASL-MRI to diagnose, grade and predict clinical outcomes for low-grade gliomas and other pediatric brain tumors.
Dr. Cole is contributing her expertise in molecular pathology and pediatric cancer genomics to this project performing temporal and spatial multi-omic single cell analyses from prospectively collected pediatric cancer patient specimens.
Researchers at the Center for Childhood Cancer Research developed and clinically evaluated carboplatin desensitization protocols for use during pediatric low-grade glioma treatment.
Researchers at the Center for Childhood Cancer Research are evaluating circulating tumor cells (CTC) and cell-free tumor DNA in blood and cerebrospinal fluid (CSF) from pediatric brain tumor patients to develop non-invasive tests for pediatric cancers.
Researchers at the Center for Childhood Cancer Research are studying evidence-based clinical criteria for treatment initiation of optic pathway gliomas and evaluating the effectiveness of various treatment options for children with these tumors.
Researchers at the Center for Childhood Cancer Research are evaluating the long-term effects of proton therapy on neurocognitive outcomes in infants and young children with a variety of pediatric brain cancers.
Researchers at the Center for Childhood Cancer Research are conducting clinical trials to determine whether or not hormonal changes in pediatric patients cause plexiform neurofibromas to grow faster.
Researchers at the Center for Childhood Cancer Research are conducting clinical trials to evaluate targeted cancer therapies for children with inoperable plexiform neurofibromas.
Research in the laboratory of Kristina A Cole, MD, PhD involves identifying the proteins required for malignant gliomas with alternative lengthening of telomeres (ALT) to continue to proliferate.
Researchers at the Center for Childhood Cancer Research are using biological analysis and clinical outcomes data to improve risk classification and treatment protocols for pediatric patients with medulloblastoma.
Identifying areas of social difficulty in pediatric brain tumor survivors and comparing them to data collected on children with autism spectrum disorder.
Children who have been treated for brain tumors can face significant social challenges post treatment.
A clinical trial is currently underway through the COG to evaluate the safety and efficacy combining a Wee1 inhibitor AZD-1775 and Irinotecan as treatment for relapsed and refractory neuroblastoma and medulloblastoma.
Researchers at the Center for Childhood Cancer Research are pioneering innovative treatments for children with retinoblastoma.